Conception is often compared to a roll of the dice. You hope for a particular outcome but know that your success depends a great deal on luck. Every step of the way, you face odds: your odds of ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

In the report, a team led by Dr. Arthur Beaudet and Dr. Sau Wai Cheung at BCM, described use of array comparative genomic hybridization to analyze samples taken during amniocentesis or chorionic ...

The cell-free fetal dna testing market is expected to have a CAGR of 10.9%. By 2023, the market is anticipated to be worth US$ 1,466.3 million, and by 2033, it’s anticipated to be worth US$ 4,124.7 ...

SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to ...

The global cell-free fetal DNA testing market is experiencing robust growth, with revenue projected to climb from USD 1,566.0 million in 2024 to USD 3,051.5 million by 2035, advancing at a CAGR of 6.1 ...

Transitioning to NGS-based workflows from microarray will hasten growth opportunities to create tests with better specificity and cost, finds Frost & Sullivan's Transformational Health team SANTA ...

So far that’s still science fiction. But scientists have been taking some baby steps in that direction. And some ethics experts say it’s time to start talking now about what that could mean for ...

Ads for three prenatal testing services for genetic conditions including Down’s syndrome have been banned for using misleading statistics about their accuracy. The Advertising Standards Authority (ASA ...

Myriad Genetics (MYGN) continues to empower parents with increased access to prenatal testing. SneakPeek is now available over the counter in more than 8,800 retail locations nationwide. The product ...